

# How does the regular standardized assessment of antipsychotic-induced side effects in forensic psychiatric patients affect the management of these side effects?

<b>Submission date</b> 12/09/2003	<b>Recruitment status</b> Stopped	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Stopped	<input type="checkbox"/> Protocol
<b>Last Edited</b> 22/08/2011	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr Albert Ngan

**Contact details**  
Pharmacy Department  
Homerton University Hospital NHS Trust  
Homerton Row  
London  
United Kingdom  
E9 6SR  
+44 020 8510 7252  
albert.ngan@homerton.nhs.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

## Secondary identifying numbers

N0024108481

# Study information

## Scientific Title

### Study objectives

To identify the effect of the introduction of two assessment scales to regularly appraise antipsychotic-induced side effects in forensic psychiatric patients on management of these side effects.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Not specified

### Study type(s)

Not Specified

## Participant information sheet

### Health condition(s) or problem(s) studied

Mental and Behavioural Disorders: Psychosis

### Interventions

1. Self-rating Anxiety Scale (SAS) & Brief Agitation Rating Scale (BARS) assessment + ongoing reassessments
2. Standard care

### Intervention Type

Other

### Phase

Not Specified

**Primary outcome measure**

Changes/differences in the SAS and BARS rating at the baseline and the end-assessment within the control and the study group and between the groups. Differences in the general mental health rating at the beginning and the end-assessment between the control and the study groups. Association between SAS + BARS assessment and the general mental health status.

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/04/2003

**Completion date**

31/10/2003

**Reason abandoned (if study stopped)**

Lack of staff

**Eligibility****Key inclusion criteria**

30 + 30 patients, Forensic Mental Health Unit.

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

60

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/04/2003

**Date of final enrolment**

31/10/2003

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**  
**Pharmacy Department**  
London  
United Kingdom  
E9 6SR

## Sponsor information

### Organisation

Department of Health (UK)

### Sponsor details

Richmond House  
79 Whitehall  
London  
United Kingdom  
SW1A 2NL

### Sponsor type

Government

### Website

<http://www.doh.gov.uk>

## Funder(s)

### Funder type

Government

### Funder Name

Homerton University Hospital NHS Trust (UK)

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

## **Individual participant data (IPD) sharing plan**

### **IPD sharing plan summary**

Not provided at time of registration